Quantcast

Latest Clinical research Stories

2014-09-01 16:22:55

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014 SummaryGlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary...

2014-09-01 16:22:40

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Sickle Cell Disease Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/689745/Sickle-Cell-Disease-Global-Clinical-Trials-Review-H2-2014.html Sickle Cell Disease Global Clinical Trials Review, H2, 2014 SummaryGlobalData's clinical trial report, "Sickle Cell Disease Global Clinical Trials Review, H2, 2014" provides data on the Sickle Cell Disease clinical trial...

2014-09-01 16:22:34

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coronary Thrombosis Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/652973/Coronary-Thrombosis-Global-Clinical-Trials-Review-H2-2014.html Coronary Thrombosis Global Clinical Trials Review, H2, 2014 SummaryGlobalData's clinical trial report, "Coronary Thrombosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Thrombosis clinical trial...

2014-09-01 16:22:29

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Coronary Vasospasm Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/648928/Coronary-Vasospasm-Global-Clinical-Trials-Review-H2-2014.html Coronary Vasospasm Global Clinical Trials Review, H2, 2014 SummaryGlobalData's clinical trial report, "Coronary Vasospasm Global Clinical Trials Review, H2, 2014" provides data on the Coronary Vasospasm clinical trial scenario....

2014-09-01 16:22:23

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Fatty Liver Disease Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html Fatty Liver Disease Global Clinical Trials Review, H2, 2014 SummaryGlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" provides data on the Fatty Liver Disease clinical trial...

2014-08-31 23:03:49

Datex Pharmaceutical Software now includes a suite of features which enables compliance of the new FDA regulation, the Drug Quality Security Act (DQSA). Clearwater FL (PRWEB) August 31, 2014 Datex Pharmaceutical Software now includes a suite of features which enables compliance of the new FDA regulation, the Drug Quality Security Act (DQSA). The FDA Drug Quality and Security Act (DQSA) was signed into law in late 2013. Established to address threats to patient safety and security, the...

2014-08-31 04:21:07

Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in the ODYSSEY LONG TERM trial TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.(...

2014-08-31 04:20:55

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial - PARIS and TARRYTOWN, N.Y., Aug. 31, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia....

2014-08-30 12:21:03

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure MARLBOROUGH, Mass., Aug. 30, 2014 /PRNewswire/ -- Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical trial investigating vagus nerve stimulation (VNS) for the treatment of heart failure patients. Faiez Zannad, M.D.,...

2014-08-29 23:09:31

On August 26, the FDA announced the recall of several sterile convenience surgical packs, by Customed Inc., due to possible loss of sterility. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) August 29, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on sterile convenience surgical packs. The US FDA...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'